PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults

The pharmacologic inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) lowers lipoprotein (a) [Lp(a)] concentrations. However, the impact of genetic PCSK9 loss-of-function variants (LOFVs) on Lp(a) is uncertain. We determined the association of PCSK9 LOFVs with Lp(a) measures among bl...

Full description

Bibliographic Details
Main Authors: Matthew T. Mefford, Santica M. Marcovina, Vera Bittner, Mary Cushman, Todd M. Brown, Michael E. Farkouh, Sotirios Tsimikas, Keri L. Monda, J. Antonio G. López, Paul Muntner, Robert S. Rosenson
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:Journal of Lipid Research
Subjects:
proprotein convertase subtilisin-kexin type 9
lipoprotein (a)
apolipoprotein
oxidized phospholipids
epidemiology
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520322926

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520322926

Similar Items